• LAST PRICE
    6.3000
  • TODAY'S CHANGE (%)
    Trending Up0.0800 (1.2862%)
  • Bid / Lots
    4.7000/ 2
  • Ask / Lots
    6.1500/ 4
  • Open / Previous Close
    6.2100 / 6.2200
  • Day Range
    Low 6.1500
    High 6.4000
  • 52 Week Range
    Low 0.0011
    High 7.7000
  • Volume
    17,557
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract
    • 6 hours ago by Newsfile
      Companies Mentioned: BHST

      Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 25, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the third quarter ended September 30, 2024.

    • 6 hours ago by Dow Jones
      Companies Mentioned: BHSC
      payable and accrued liabilities 1,341 1,632 Cash used in operations (4,295) (5,439) -------------------------------------------------------------------- ------- ----------- Interest paid - (89) -------------------------------------------------------------------- ------- ----------- Net cash used in operating activities (4,295) (5,528) Cash flow from investing activities: Purchase of property and equipment (2,442) (1,183) Deposit of restricted cash for bank guarantee, net of drawing (185) - Net cash used in investing activities (2,627) (1,183) -------------------------------------------------------------------- ------- ----------- Cash flow from financing activities: Payments of lease liabilities (412) (274) Exercise of options 408 403 Net proceeds from issuance of units of securities 4,330 - Proceeds from issuance of Convertible loans - 6,418 Net cash provided by financing activities 4,326 6,547 -------------------------------------------------------------------- ------- ----------- Exchange rate differences on cash and cash equivalents 9 (13) Decrease in cash and cash equivalents (2,596) (164) Cash and cash equivalents at the beginning of the period 5,355 1,736 Cash and cash equivalents at the end of the period $ 2,768 $ 1,559 -------------------------------------------------------------------- ------- ----------- Significant non-cash transactions: Conversion of convertible loans into common shares and warrants 20,527 2,557 Purchase of property in installment agreement 1,721 - Recognition of right of use assets and lease liabilities 8,648 - Reclassification of warrants as an equity instrument 934 -
    • 13 hours ago by Newsfile
      Companies Mentioned: BHST

      Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 25, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of its highly anticipated VINIA® infused teas - a line of SuperFood functional teas that deliver the same clinically validated benefits as the successful VINIA® supplements. This launch further demonstrates the potential of VINIA's lifetime value across multiple consumer verticals.

    • 13 hours ago by Dow Jones
      Companies Mentioned: BHSC

      Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 25, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of its highly anticipated VINIA(R) infused teas - a line of SuperFood functional teas that deliver the same clinically validated benefits as the successful VINIA(R) supplements. This launch further demonstrates the potential of VINIA's lifetime value across multiple consumer verticals.
  • Nov 21, 2024

Peers Headlines

No documents available